The acute treatment of migraine with sumatriptan in children (CROSBI ID 546463)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Cvitanović, Ljerka ; Mučić, Branka ; Šepić Grahovac, Dubravka ; Hajnzić, Tomislav-Franjo ; Mataija, Marina ; Sojat, T.
engleski
The acute treatment of migraine with sumatriptan in children
Headache (HD), one of the commonest neurological symptoms in childhood, may be very disturbing and can prevent children from their everyday activity. Acute HD is usually treated by paediatricians ; only a small number of cases is sent to a neuropediatric outpatient clinic. On the hand, chronic recurrent HD is very often carefully evaluated by neuropediatricians. Migraine is difficult to diagnose with certainty in children whose ability to report previous or changing symptoms may be limited. The prevalence of migraine is 2.5% in children under the age of 7 years (yrs), 5% in children from 7 yrs to puberty. From 1995 to 1998, 150 children have been analysed to our Neuropediatric Unit because of chronic HD. A type of HD was defined according to the Headache Classification Committee of the International Headache Society (Cephalalgia 1993 ; 12: 238-244). Migraine was the diagnosis in 6% of children (5 girls and 4 boys). The age of the 9 children at the establishment of the diagnosis of migraine ranged from 6 to 12 yrs. The mean period of duration of symptoms prior to making the diagnosis was 1.4 yrs. The period of follow up subsequent to making diagnosis of migraine was 6 months to 4.4 yrs. Oral Sumatriptan was given to all patients (50 mg or 100 mg in the treatment of one migraine attack). In 7 patients efficacy was excellent in 30 to 60 minutes, no recurrence was seen during the same attack, time between attacks was longer, 5 patients became attack free. One girl had the same frequency of attacks and the efficacy was sub-optimal. Only one girl had chest and abdominal discomfort. Sumatriptan is an effective treatment for acute migraine in children as young as 6 yrs of age. The recurrence rate was either reduced or the children became attack free. Only one child had transient side effects, which were not tolerated.
Migraine; Childhood; Sumatriptan
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
1999.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Abstracts
Turku: ICHCA
Podaci o skupu
IV International Congress on Headache in Childhood and Adolescence
predavanje
02.09.1999-04.09.1999
Turku, Finska